Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,243,522
  • Shares Outstanding, K 126,492
  • Annual Sales, $ 1,828 M
  • Annual Income, $ -440,240 K
  • 60-Month Beta 0.30
  • Price/Sales 16.96
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ALNY with:

Options Overview Details

View History
  • Implied Volatility 34.71% ( +1.21%)
  • Historical Volatility 88.74%
  • IV Percentile 5%
  • IV Rank 2.06%
  • IV High 149.76% on 06/21/24
  • IV Low 32.29% on 06/26/24
  • Put/Call Vol Ratio 0.85
  • Today's Volume 5,269
  • Volume Avg (30-Day) 3,991
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 59,945
  • Open Int (30-Day) 51,953

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.23
  • Number of Estimates 11
  • High Estimate -0.84
  • Low Estimate -1.76
  • Prior Year -2.21
  • Growth Rate Est. (year over year) +44.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.79 +65.54%
on 05/30/24
252.87 -3.90%
on 06/27/24
+92.94 (+61.94%)
since 05/28/24
3-Month
141.98 +71.16%
on 04/25/24
252.87 -3.90%
on 06/27/24
+93.55 (+62.60%)
since 03/28/24
52-Week
141.98 +71.16%
on 04/25/24
252.87 -3.90%
on 06/27/24
+46.44 (+23.63%)
since 06/28/23

Most Recent Stories

More News
Stocks Settle Mixed on Weakness in Tech Stocks

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.15%. Stock indexes...

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
ZNU24 : 109-315s (-0.24%)
SMCI : 819.35 (-7.98%)
NVDA : 123.54 (-0.36%)
QCOM : 199.18 (+2.07%)
MRVL : 69.90 (+1.70%)
AVGO : 1,605.53 (+1.19%)
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024

Stocks that traded heavily or had substantial price changes on Monday: RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall

UAA : 6.67 (-2.63%)
DIS : 99.29 (-2.82%)
SON : 50.72 (-1.78%)
RMD : 191.42 (-0.08%)
ALNY : 243.00 (-1.62%)
Stocks Mixed as Chip Stock Weakness Weighs on the Nasdaq 100

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%. Stock indexes today are mixed,...

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
ZNU24 : 109-315s (-0.24%)
SMCI : 819.35 (-7.98%)
NVDA : 123.54 (-0.36%)
QCOM : 199.18 (+2.07%)
MRVL : 69.90 (+1.70%)
AMAT : 235.99 (+1.49%)
Equity Market Indexes are Mixed Today Due to Tech Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) today is up +0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.99%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.34%. Stock indexes today are mixed....

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
ZNU24 : 109-315s (-0.24%)
META : 504.22 (-2.95%)
IBM : 172.95 (+1.23%)
TGT : 148.04 (+0.90%)
RXO : 26.15 (+4.85%)
ALNY : 243.00 (-1.62%)
Alnylam: Q1 Earnings Snapshot

Alnylam: Q1 Earnings Snapshot

ALNY : 243.00 (-1.62%)
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

/CNW/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets,...

ALNY : 243.00 (-1.62%)
Why Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

BMO : 83.85 (+0.66%)
ALNY : 243.00 (-1.62%)
Alnylam: Q4 Earnings Snapshot

Alnylam: Q4 Earnings Snapshot

ALNY : 243.00 (-1.62%)
Alnylam: Q3 Earnings Snapshot

Alnylam: Q3 Earnings Snapshot

ALNY : 243.00 (-1.62%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...

ALNY : 243.00 (-1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 256.18
2nd Resistance Point 252.75
1st Resistance Point 247.87
Last Price 243.00
1st Support Level 239.56
2nd Support Level 236.13
3rd Support Level 231.25

See More

52-Week High 252.87
Last Price 243.00
Fibonacci 61.8% 210.51
Fibonacci 50% 197.42
Fibonacci 38.2% 184.34
52-Week Low 141.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar